2022年1月26日简报:奥密克戎病例约占全美新病例的99.9%;奥密克戎亚型突变株BA.2的病例正在增加;辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验

2022-01-26 MedSci整理 MedSci整理

截至北京时间2022年1月26日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿5889万例,新增3,173,181例,达到358,895

截至北京时间2022年1月26日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过3亿5889万例,新增3,173,181例,达到358,895,982例。累计死亡病例563.3万例,达到5,633,024例。新增死亡为9,268例。康复为284,404,801例,重症和危重症病人达到95,838例;全球新冠确诊病例超过100万例的国家达47个,119个国家病例超10万例。昨日报道:2022年1月25日简报:不应该过度贩卖奥密克戎焦虑或过度轻视;奥密克戎的一个亚变种BA.2引发关注;权威杂志确证奥密克戎病毒复制能力和致病力均下降;

美国CDC:感染奥密克戎病例约占全美新病例的99.9%

据美国疾病预防控制中心(CDC)的最新建模数据显示,截至1月22日,感染奥密克戎变异毒株的病例约占美国所有新病例的99.9%。

2021年12月初时,CDC估计奥密克戎病例仅占全美新病例的0.6%。

预测人员人员估计,目前,感染德尔塔变异毒株病例仅占全美新病例的0.1%。

世卫警告:感染奥密克戎亚型突变株BA.2的病例正在增加

当地时间1月25日,世界卫生组织在其网站上更新了一篇文章,称这种奥密克戎亚型毒株名为BA.2,是目前占主导地位的奥密克戎变异毒株的后代。与奥密克戎不同,BA.2目前并不被认为是“值得关注的变体”;但由于它正在许多国家传播,世界卫生组织正在要求全球各国政府和科学家监测这一趋势,并研究这种新的亚型毒株。

目前,一些国家已经在这样做了。

截至上周五,BA.2已经在包括美国在内的至少40个国家被发现,并已在丹麦和英国迅速传播,早期的报告显示它似乎并不比奥密克戎原始毒株更致命。

虽然BA.2是奥密克戎的后代,但它的突变形式略有不同。研究人员已发现奥密克戎存在几个亚型变异毒株,和以前占主导地位的德尔塔变异毒株一样。

北京1月25日新增14例本土确诊病例、5例无症状感染者

1月25日0时至24时,北京新增14例本土确诊病例(确诊病例1至12昨日均已通报)和5例无症状感染者(无症状感染者1至3昨日均已通报),无新增疑似病例;新增1例境外输入确诊病例和14例无症状感染者,无新增疑似病例。

北京本轮感染者67例:奥密克戎关联6例,德尔塔关联61例

今天(1月25日),北京市召开第275场新冠肺炎疫情防控工作新闻发布会。发布会上,北京市疾病预防控制中心副主任庞星火介绍,1月15日以来北京市已累计报告本土新冠肺炎病毒感染者67例,其中奥密克戎变异株关联疫情累计报告6例均为确诊病例,为轻型。德尔塔变异株关联疫情目前累计报告病例61例,确诊病例47例,其中轻型32例,普通型15例,无症状感染者14例。

张颖:从天津本轮疫情感染者来看,奥密克戎不能被当做“大号流感”

1月25日,天津市疾控中心副主任张颖接受采访。张颖认为,奥密克戎是否是大号流感,还需要继续观察,需要更多证据。但从天津这起疫情病例临床表现来看,确实它不能被看作是大号流感。在天津361例阳性感染者里面,有42%是普通型,从临床诊断上来说,普通型无论是轻还是重,是有肺炎的表现。对于疾病来说,如果有肺炎占比能达到42%,就不能等同于大号流感。因为我们都知道流感病毒所造成的疾病是以上呼吸道症状为主,会有慢性基础性疾病的人群,会合并肺炎,细菌性的肺炎或病毒性的肺炎,但比例是远远要少于42%的构成比。就目前天津疫情来说,我个人觉得对它是大号流感持一个观望,还是需要在临床上继续来观察。

辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验

1月25日消息,辉瑞和BioNTech已就专门针对奥密克戎毒株的新冠疫苗启动临床试验。

两家制药商周二表示,他们开始在美国和南非招募18至55岁成年人,以检查疫苗的安全性、耐受性和产生的免疫反应。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652512, encodeId=e6b31652512ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 01 01:23:46 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919382, encodeId=1cc41919382bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 31 00:23:46 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391198, encodeId=77701391198f0, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Thu Jan 27 23:23:46 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188674, encodeId=450e11886e427, content=按照疫情防控,还是取得了重大成就, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78436484750, createdName=ms3000000005889368, createdTime=Thu Jan 27 21:09:01 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188212, encodeId=ba3911882126d, content=❛˓◞˂̵✧, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a05627756, createdName=ms6000001119630465, createdTime=Wed Jan 26 08:39:31 CST 2022, time=2022-01-26, status=1, ipAttribution=)]
    2022-10-01 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652512, encodeId=e6b31652512ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 01 01:23:46 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919382, encodeId=1cc41919382bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 31 00:23:46 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391198, encodeId=77701391198f0, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Thu Jan 27 23:23:46 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188674, encodeId=450e11886e427, content=按照疫情防控,还是取得了重大成就, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78436484750, createdName=ms3000000005889368, createdTime=Thu Jan 27 21:09:01 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188212, encodeId=ba3911882126d, content=❛˓◞˂̵✧, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a05627756, createdName=ms6000001119630465, createdTime=Wed Jan 26 08:39:31 CST 2022, time=2022-01-26, status=1, ipAttribution=)]
    2022-05-31 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652512, encodeId=e6b31652512ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 01 01:23:46 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919382, encodeId=1cc41919382bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 31 00:23:46 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391198, encodeId=77701391198f0, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Thu Jan 27 23:23:46 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188674, encodeId=450e11886e427, content=按照疫情防控,还是取得了重大成就, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78436484750, createdName=ms3000000005889368, createdTime=Thu Jan 27 21:09:01 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188212, encodeId=ba3911882126d, content=❛˓◞˂̵✧, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a05627756, createdName=ms6000001119630465, createdTime=Wed Jan 26 08:39:31 CST 2022, time=2022-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652512, encodeId=e6b31652512ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 01 01:23:46 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919382, encodeId=1cc41919382bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 31 00:23:46 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391198, encodeId=77701391198f0, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Thu Jan 27 23:23:46 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188674, encodeId=450e11886e427, content=按照疫情防控,还是取得了重大成就, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78436484750, createdName=ms3000000005889368, createdTime=Thu Jan 27 21:09:01 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188212, encodeId=ba3911882126d, content=❛˓◞˂̵✧, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a05627756, createdName=ms6000001119630465, createdTime=Wed Jan 26 08:39:31 CST 2022, time=2022-01-26, status=1, ipAttribution=)]
    2022-01-27 ms3000000005889368

    按照疫情防控,还是取得了重大成就

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1652512, encodeId=e6b31652512ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 01 01:23:46 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919382, encodeId=1cc41919382bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 31 00:23:46 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391198, encodeId=77701391198f0, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Thu Jan 27 23:23:46 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188674, encodeId=450e11886e427, content=按照疫情防控,还是取得了重大成就, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78436484750, createdName=ms3000000005889368, createdTime=Thu Jan 27 21:09:01 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188212, encodeId=ba3911882126d, content=❛˓◞˂̵✧, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71a05627756, createdName=ms6000001119630465, createdTime=Wed Jan 26 08:39:31 CST 2022, time=2022-01-26, status=1, ipAttribution=)]
    2022-01-26 ms6000001119630465

    ❛˓◞˂̵✧

    0

相关资讯

第四针疫苗对奥密克戎保护力欠佳,全球疫情或将迎来新一波峰值丨新冠研究一周进展

近日,发表于预印本平台medRxiv的一项研究,比较了奥密克戎流行前后,美国5岁以下儿童(未接种疫苗)首次感染新冠病毒后的疾病严重程度。

bioRxiv:国际邮件和海淘会导致奥密克戎感染吗?

近日,北京、深圳各有一例新冠病毒感染病例溯源工作在排除其他可能传染源之后,将源头定位于病毒核酸检测阳性的国际邮件。新闻报道并未说明是否检测出活新冠病毒,而不具致病能力的病毒核酸片段亦可导致核酸阳性,这

2022年1月24日简报:世卫组织预计到3月份,奥密克戎或将使新冠疫情接近尾声;多国切换至奥密克戎应对模式

截至北京时间2022年1月24日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿5190万例,新增2,157,815例,达到351,906

2022年1月25日简报:不应该过度贩卖奥密克戎焦虑或过度轻视;奥密克戎的一个亚变种BA.2引发关注;权威杂志确证奥密克戎病毒复制能力和致病力均下降;

截至北京时间2022年1月25日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿5401万例,新增1,901,236例,达到354,501

2022年1月22日简报:加强针可将奥密克戎引起的住院风险降低90%;丹麦感染奥密克戎BA.2亚型毒株病例已占到45%;日本新增确诊逼近5万例,国内31省新增23例

截至北京时间2022年1月22日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿4672万例,新增3,569,610例,达到346,723

2022年1月23日简报:儿童感染奥密克戎后症状轻微;奥密克戎已在大多数国家取代德尔塔,不应恐惧奥密克戎!奥密克戎约有40-80%为无症状感染

截至北京时间2022年1月23日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过3亿4970万例,新增2,795,074例,达到349,706